About 100 reports

BUYER' S POWER - Moderate ##.

  • Neurological Disorder
  • World
  • Market Size
  • Cardinal Health, Inc.
  • Eckert & Ziegler AG

Aphria runs a greenhouse to produce cannabis in Leamington, Ontario, called Aphria One.

  • Marijuana
  • Neurological Disorder
  • World
  • Market Size
  • Canopy Growth Corporation

Less substitute. ##.

  • Neurological Disorder
  • World
  • AstraZeneca PLC
  • Biogen Idec Inc.
  • Eli Lilly & Co.

They also have an increased risk of Parkinson' s disease, and cancers such as myeloma, leukemia and lymphoma.

  • Neurological Disorder
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.

Impact: ## Low; ## High F.

  • Neurological Disorder
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Flamel Technologies S.A.
  • Pfizer Inc.

THE COMPANY STATES THAT THESE ARE DESIGNED AS PER THE NORMS OF DIN ISO ##-## AND ##-##.

  • Neurological Disorder
  • World
  • Forecast
  • Antares Pharma, Inc.
  • Sanofi S.A.

Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Pharmaceuticals and Healthcare No. of Deals ## ## ## ## ## ## Deal Value (US$ million) NA NA NA NA NA NA Note: Deals include all announced pharmaceuticals & healthcare

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Stroke
  • United States

(USA) ##.

  • Neurological Disorder
  • Europe
  • United States
  • World
  • Market Shares

This condition is called lymphoplasmacytic lymphoma.

  • Autoimmune Disease
  • Infectious Disease
  • Neurological Disorder
  • Therapy
  • United States
  • SP-1161 - DRUG PROFILE

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • AstraZeneca PLC
  • Mechanism Of Action

As of December 2013, it was in Phase I stage for prolymphocytic leukemia (PLL), hairy cell leukemia (HCL), indolent b-cell l lymphoma, Burkitt lymphoma, acute lymphocytic leukemia.

  • Cancer
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • SP-1161 - DRUG PROFILE

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • AstraZeneca PLC
  • Mechanism Of Action

Its products are used for the treatment of various tumors such as multiple myeloma, lymphoma, leukemia, neuroblastoma, retinoblastoma and lung cancer.

  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • AstraZeneca PLC

NHL Efficacy highlights include: Response Rates observed in patients with NHL: ## percent (## of ##) ORR, including one CR in patients with Marginal Zone Lymphoma (MZL), ## percent (## of ##) ORR, including ## percent CR rate in patients with Mantle Cell Lymphoma (MCL), ## p

  • Monoclonal Antibody
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • Alexion Pharmaceuticals, Inc.

April ##, 2017, ##:## - ##:## p. m.

  • Neurological Disorder
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

RN-## acts by targeting lysine specific demethylase-## (LSD-##).

  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • Oryzon Genomics S.A.

NHL Efficacy highlights include: Response Rates observed in patients with NHL: ## percent (## of ##) ORR, including one CR in patients with Marginal Zone Lymphoma (MZL), ## percent (## of ##) ORR, including ## percent CR rate in patients with Mantle Cell Lymphoma (MCL), ## p

  • Monoclonal Antibody
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • Alexion Pharmaceuticals, Inc.

DTX##, in Phase ## for the treatment of ornithine transcarbamylase (OTC) deficiency; DTX## in Phase ## for the treatment of GSDIa, and DTX## in Phase ## for the treatment of hemophilia A.

  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Genzyme Corporation

Patients will be on up to two background therapies and will be randomized one-to-one to bardoxolone methyl or placebo.

  • Chronic Disease
  • Neurological Disorder
  • United States
  • Product Initiative
  • RPI
  • MYASTHENIA GRAVIS - PIPELINE BY IMCYSE SA, H2 2018
  • MYASTHENIA GRAVIS - PIPELINE BY HANALL BIOPHARMA CO LTD, H2 2018

Following achievement of a dosage that effectively managed the patient' s symptoms, the patients were randomized ##:## into one of two crossover treatment groups.

  • Neurological Disorder
  • Therapy
  • United States
  • Product Initiative
  • Protalex, Inc.

It is in Phase I stage for acute myelocytic leukemia, chronic myelocytic leukemia, myelodysplastic syndrome, Burkitt lymphoma, lymphoplasmacytic lymphoma, T-cell lymphoma and mantle cell lymphoma.

  • Neurological Disorder
  • Therapy
  • United States
  • Product Initiative
  • Viking Therapeutics, Inc.

Sphingosine ##-Phosphate Receptor ## (Endothelial Differentiation G Protein Coupled Receptor ## or Sphingosine ## Phosphate Receptor Edg ## or CD## or S##PR##) - Overview Sphingosine-##-phosphate receptor ## (S##P receptor ## or S##P##) is

  • Neurological Disorder
  • United States
  • World
  • Product Initiative
  • Novartis AG

## ## ## ## Pfizer Inc Omnicare Pharma Gmbh Merck & Co Inc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Humanigen Inc ## ## ## ## ## ## Eisai Co Ltd ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## Bio

  • Neurological Disorder
  • Neurology
  • Therapy
  • World
  • Product Initiative

Under the offering, the entitlement ratio will be ##:##.

  • Cell Therapy
  • Neurological Disorder
  • United States
  • Product Initiative
  • Sarepta Therapeutics, Inc.

It is in Phase II stage of development for the treatment of glioma, refractory/ relapsed follicular lymphoma, B-cell non-hodgkin lymphoma, mantle cell lymphoma, indolent lymphoma, refractory/ relapsed acute myeloid leukemia, metastatic soft tissue sarcoma, non-smal

  • Neurological Disorder
  • Therapy
  • United States
  • Product Initiative
  • CTD Holdings, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Neurological Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • CSL Limited
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Hospital
  • Neurological Disorder
  • World
  • Product Initiative

Sphingosine ## Phosphate Receptor Edg ## or CD## or Sphingosine ##-Phosphate Receptor ## (Endothelial Differentiation G Protein Coupled Receptor ## or S##PR##) - Pipeline Review, H## 2018 Reference Code: GMDHC##TDB Publication Date: August 2018 LIST OF TABLES

  • Neurological Disorder
  • United States
  • World
  • Product Initiative
  • Novartis AG

In this Phase I trial, patients with inoperable or metastatic advanced solid tumors or lymphomas will be treated with increasing doses of trigriluzole in combination with nivolumab and other PD-## blocking immunotherapies.

  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Food and Drug Administration (FDA) approved RITUXAN HYCELA& trade(rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse

  • Neurological Disorder
  • Therapy
  • United States
  • Company
  • Biogen Idec Inc.